Eukaryotic translation initiation machinery (eIFs)

The eukaryotic translation initiation machinery is a complex multi-protein assembly, primarily centered around eukaryotic translation initiation factors (eIFs), that coordinates the recruitment of the 40S ribosomal subunit to the 5' cap of mRNA. This process is the rate-limiting step of protein synthesis and serves as a major regulatory hub for cell growth and proliferation, often controlled by the PI3K/AKT/mTOR signaling pathway (Bhat et al., 2015, Nature Reviews Drug Discovery). The core of this machinery is the eIF4F complex, which includes the cap-binding protein eIF4E, the RNA helicase eIF4A, and the large scaffolding protein eIF4G (Pelletier et al., 2015, Nature Reviews Cancer). In many cancers, this machinery is dysregulated or overexpressed, leading to the selective translation of oncogenic mRNAs that promote survival, angiogenesis, and metastasis (UniProt P06730, P60842). Therapeutic interventions targeting this machinery include mTOR inhibitors that prevent eIF4F formation and newer small molecules like Zotatifin and Tomivosertib that directly target eIF4A or the kinases that activate eIF4E (ClinicalTrials.gov). While highly effective at inhibiting tumor growth in preclinical models, the essential nature of translation in all cells requires careful management of systemic toxicity to maintain a viable therapeutic window.

Other names

Eukaryotic translation initiation factorseIF complexeIF4F complexProtein synthesis initiation machineryTranslation initiation factor complex

Inhibition of eIF4F complex assembly, inhibition of eIF4A RNA helicase activity, competitive inhibition of eIF4E-m7G cap binding, and inhibition of MNK1/2-mediated phosphorylation of eIF4E.